MaaT Pharma Shares 2024 Business Update and Key Milestones

MaaT Pharma, a clinical-stage biotechnology company, continues to make significant strides in advancing its therapeutic pipeline focused on Microbiome Ecosystem TherapiesTM (MET) for enhancing cancer patient survival. The company recently delivered a business update highlighting key milestones expected in 2024.

Hervé Affagard, CEO and co-founder of MaaT Pharma, expressed optimism about the company's progress, particularly the Phase 3 results for MaaT013. He emphasized MaaT013's potential in treating acute graft-versus-host disease (aGvHD) and the company's partnerships aimed at exploring MaaT033's impact on immune checkpoint inhibitors in non-small cell lung cancer.

Key highlights include the positive efficacy and safety data for MaaT013 in aGvHD patients presented at the European Society for Blood and Marrow Transplantation (EBMT) 2024 annual meeting. The data from the Early Access Program indicated a 63% gastrointestinal overall response rate (GI-ORR) at day 28, with overall survival rates of 49% at one year and 42% at 18 months in patients similar to those involved in the ARES Phase 3 clinical trial. These results are promising when compared to historical data, showing a significant improvement in survival rates.

The company anticipates the primary endpoint readout for the GI-ORR at day 28 from the ARES Phase 3 clinical trial in mid-Q4 2024. Additionally, MaaT Pharma has announced the completion of patient recruitment for the Phase 2a clinical trial PICASSO, which is evaluating MaaT013 in combination with immune checkpoint inhibitors. Topline results from this trial are expected in late 2024 or early 2025.

MaaT Pharma is also participating in the IMMUNOLIFE program, aimed at addressing primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. As part of this consortium, MaaT033 will be tested in a Phase 2 randomized multicenter clinical trial to increase the response rate to anti-PD1 therapy.

In the area of neurodegenerative diseases, the company announced the completion of patient recruitment for the Phase 1 clinical trial IASO, assessing MaaT033 for patients with Amyotrophic Lateral Sclerosis (ALS). The Data Safety and Monitoring Board reviewed safety data from the first eight patients and recommended the continuation of the trial without modifications.

MaaT Pharma is also advancing MaaT034, a candidate for immuno-oncology. New in vitro data presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting showcased the metabolites produced by MaaT034 and their role in immune modulation. These findings represent a significant step towards clinical evaluation of co-cultured microbiome therapies.

On the corporate front, MaaT Pharma appointed Jonathan Chriqui as Chief Business Officer, enhancing the company’s business development and partnership strategies. The company has also announced the production of batches of MaaT013 for clinical supply in the U.S. as it prepares for study initiation.

Despite having sufficient cash to finance operations until the end of Q3 2024, MaaT Pharma is actively seeking additional funding to extend its cash runway beyond this period.

Key milestones for 2024 include the primary endpoint readout for the ARES Phase 3 trial in mid-Q4, topline results from the PICASSO Phase 2a trial in late 2024/early 2025, initial results from the IASO Phase 1 trial in ALS in the second half of 2024, and the start of production for the first cGMP batch of MaaT034 in the second half of 2024.

MaaT Pharma remains committed to advancing its pipeline and exploring new opportunities in the microbiome field to improve patient outcomes in oncology and beyond.